(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 203MM | +9% |
Gross Profit | 177.7MM | +10% |
Cost Of Revenue | 25.3MM | +3% |
Operating Income | 43.3MM | -1% |
Operating Expenses | 134.4MM | - |
Net Income | 44.3MM | +27% |
R&D | 42.3MM | +7% |
G&A | 24.9MM | +16% |
Marketing | 67.2MM | +18% |
Interest Expense | 3MM | +18% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.
Shares of Trump Media surge for a second day, GameStop’s fiscal fourth-quarter revenue misses analysts’ estimates, Merck’s treatment for pulmonary arterial hypertension receives FDA approval, and Cintas raises fiscal 2024 guidance.
Shockwave Medical shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Shares of Trump Media surge for a second day, GameStop’s fiscal fourth-quarter revenue misses analysts’ estimates, Merck’s treatment for pulmonary arterial hypertension receives FDA approval, and Cintas raises fiscal 2024 guidance.
The healthcare giant could follow up its $16.6 billion acquisition of Abiomed with another deal for a heart device company, the WSJ reported Tuesday.
Johnson & Johnson (JNJ) is in talks to acquire Shockwave Medical (SWAV), according to a report from The Wall Street Journal. Shockwave is a medical device maker that specializes in making cardiovascular products. Given the company's nearly $12 billion market cap, it could be an expensive deal for Johnson & Johnson, though the report says it is possible talks could fall apart. Yahoo Finance's Anjalee Khemlani discusses the report in the video above. For more expert insight and the latest market ...
The California-based maker of medical devices that treat cardiovascular diseases has a market value of nearly $12 billion.
A deal could be finalized in the coming weeks if talks don't fall apart and it is also possible another suitor could emerge, the report said, citing people familiar with the matter. WSJ's is the latest media report on a potential bid for Shockwave Medical after Bloomberg News reported last year that Boston Scientific was weighing an offer for the heart device maker. When contacted for comment on the WSJ report, J&J and Shockwave Medical said they do not comment on rumors or speculation.
Shares of Shockwave Medical rose after the Journal reported that Johnson & Johnson is in talks to acquire the medical-device maker. Shockwave's stock was recently up more than 8%. Johnson & Johnson was little changed.
SANTA CLARA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from Monday, April 8 to Thursday, April 11, 2024. Shockwave’s management is scheduled for a live fireside chat on Tuesday, April 9,